View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 5, 2011

Onbrez Inhalation Capsules Receive Japanese Regulatory Approval

The Japanese Ministry of Health, Labour and Welfare has approved Novartis' once-daily Onbrez inhalation capsules (indacaterol), 150µg, for the treatment of chronic obstructive pulmonary disease. Onbrez is delivered using the Breezhaler device and helps to reduce the symptoms of bre

By cms admin

The Japanese Ministry of Health, Labour and Welfare has approved Novartis’ once-daily Onbrez inhalation capsules (indacaterol), 150µg, for the treatment of chronic obstructive pulmonary disease.

Onbrez is delivered using the Breezhaler device and helps to reduce the symptoms of breathlessness, cough and sputum in chronic obstructive pulmonary disease patients by increasing bronchodilation.

The 12-week Phase III study of the drug, conducted in Japan and five other Asian countries, involved 347 patients and showed improved lung function and quality of life while also reducing breathlessness.

The US Food and Drug Administration is expected to complete its review of an application for the drug later this month.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology